A Study of the Safety and Efficacy of MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-289 AM2)

This study is currently recruiting participants.
Verified April 2014 by Merck Sharp & Dohme Corp.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT01760447
First received: January 2, 2013
Last updated: April 1, 2014
Last verified: April 2014

January 2, 2013
April 1, 2014
February 2013
January 2016   (final data collection date for primary outcome measure)
  • Change from baseline in hemoglobin A1c (A1C) [ Time Frame: Baseline and Week 20 ] [ Designated as safety issue: No ]
  • Number of participants who experienced at least one adverse event [ Time Frame: up to 54 weeks ] [ Designated as safety issue: Yes ]
  • Number of participants who discontinued study drug due to an adverse event [ Time Frame: Up to 54 weeks ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01760447 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Study of the Safety and Efficacy of MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-289 AM2)
A Phase III Multicenter, Double-blind, Randomized, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A XR (a Fixed-dose Combination Tablet of Sitagliptin and Extended-release Metformin) in Pediatric Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy

The purpose of this study is to assess the safety and efficacy of the addition of sitagliptin (administered as MK-0431A XR) compared with the addition of placebo to therapy with extended-release metformin (metformin XR) for the treatment of type 2 diabetes mellitus (T2DM) in pediatric participants with inadequate glycemic control on metformin monotherapy. The primary hypothesis is that the addition of sitagliptin reduces hemoglobin A1c (A1C) more than the addition of placebo after 20 weeks of treatment.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Type 2 Diabetes Mellitus
  • Drug: MK-0431A XR
    MK-0431A XR fixed-dose combination tablet (sitagliptin/metformin: 50/500 mg, 50/1000 mg) administered prior to the morning meal
  • Drug: Placebo to MK-0431A XR
    Matching placebo to MK-0431A XR fixed-dose combination tablet administered prior to the morning meal
  • Drug: Metformin XR
    Metformin XR tablet (500 mg, 1000 mg) administered prior to the morning meal
    Other Name: Glucophage® XR
  • Drug: Placebo to metformin XR
    Matching placebo to metformin XR tablet administered prior to the morning meal
  • Drug: Insulin glargine
    The insulin regimen and dosing will be at the discretion of the investigator (based on locally accepted, national, or international guidelines for the indication and use of insulin glargine)
    Other Name: Lantus
  • Experimental: MK-0431A XR
    Phase A: two MK-0431A XR tablets orally daily (total daily dose: 100 mg sitagliptin and 1000, 1500 or 2000 mg metformin) plus two placebo to metformin XR tablets for 20 weeks. Insulin glargine may be administered as glycemic rescue therapy during Phase A of the study. Phase B: two MK-0431A XR tablets orally daily (total daily dose: 100 mg sitagliptin and 1000, 1500 or 2000 mg metformin) plus two placebo to metformin XR tablets for 34 weeks. Insulin glargine may be administered during Phase B of the study depending on the participants' glucose and A1C levels.
    Interventions:
    • Drug: MK-0431A XR
    • Drug: Placebo to metformin XR
    • Drug: Insulin glargine
  • Active Comparator: Metformin XR
    Phase A: two placebo to MK-0431A XR tablets orally daily plus two metformin XR tablets (total daily dose: 1000, 1500 or 2000 mg) for 20 weeks. Insulin glargine may be administered as glycemic rescue therapy during Phase A of the study. Phase B: two placebo to MK-0431A XR tablets orally daily plus two metformin XR tablets (total daily dose: 1000, 1500 or 2000 mg) for 34 weeks. Insulin glargine may be administered during Phase B of the study depending on the participants' glucose and A1C levels.
    Interventions:
    • Drug: Placebo to MK-0431A XR
    • Drug: Metformin XR
    • Drug: Insulin glargine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
240
September 2016
January 2016   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Has T2DM
  • Has not received treatment with insulin for at least 6 months prior to study participation
  • A1C greater than or equal to 7.0% and less than or equal to 10.0% on metformin immediate release (IR) or extended release (ER), greater than or equal to 1500 mg/day, for greater than or equal to 12 weeks. NOTE: Participants on a daily dose of metformin greater than or equal to 1000 mg/day, but less than 1500 mg/day for greater than or equal to 12 weeks may be eligible if there is documentation that higher doses are not tolerated.
  • Between 10 and 17 years of age (inclusive)
  • Male, or female who is unlikely to conceive (non-sterilized, and is not sexually active or agrees to abstain from heterosexual activity or agrees to use an adequate method of contraception) during the study and for 14 days after the last dose of study drug

Exclusion Criteria:

  • Has type 1 diabetes mellitus
  • Has monogenic diabetes or secondary diabetes
  • Has previously taken a dipeptidyl peptidase IV (DPP-4) inhibitor (such as sitagliptin, vildagliptin, alogliptin, saxagliptin, or linagliptin) or glucagon-like peptide-1 (GLP-1) receptor agonist (such as exenatide or liraglutide)
  • Is on or likely to require treatment for > or =2 consecutive weeks or repeated courses of corticosteroids (inhaled, nasal and topical corticosteroids are permitted)
  • Has undergone a surgical procedure within 4 weeks of study participation or has planned major surgery during the study
  • History of congenital heart disease or cardiovascular disease other than hypertension
  • History of active liver disease (other than non-alcoholic steatosis), including chronic active hepatitis B or C, primary biliary cirrhosis, or symptomatic gallbladder disease
  • Active neuropathy (such as nephrotic syndrome or glomerulonephritis)
  • Chronic myopathy, mitochondrial disorder or a progressive neurological or neuromuscular disorder
  • Human immunodeficiency virus (HIV)
  • Hematological disorder (such as aplastic anemia, thrombocytopenia, myeloproliferative or myelodysplastic syndromes)
  • Is currently being treated for hyperthyroidism or is on thyroid hormone therapy and has not been on a stable dose for at least 6 weeks
  • History of malignancy for < or =5 years prior to study participation, except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer
  • History of idiopathic acute pancreatitis or chronic pancreatitis
  • History of recreational or illicit drug use, or of alcohol abuse or

dependence (within the past year)

  • Has donated blood products or has had phlebotomy of >10% of estimated

total blood volume within 8 weeks of study participation, or intends to donate

blood products or receive blood products within the projected duration of the study

  • Is pregnant or breast-feeding, or is expecting to conceive or donate eggs during the study, including 14 days following the last dose of study drug
Both
10 Years to 17 Years
No
Contact: Toll Free Number 1-888-577-8839
United States,   Australia,   Canada,   Chile,   Colombia,   Czech Republic,   Denmark,   Israel,   Italy,   Mexico,   Panama,   Philippines,   Russian Federation,   South Africa
 
NCT01760447
0431A-289, 2012-004035-23
Yes
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
Not Provided
Not Provided
Merck Sharp & Dohme Corp.
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP